Showing 1 - 10 of 10,920
Persistent link: https://www.econbiz.de/10003789378
Persistent link: https://www.econbiz.de/10003490618
Persistent link: https://www.econbiz.de/10008904759
Persistent link: https://www.econbiz.de/10009666236
Persistent link: https://www.econbiz.de/10012098220
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz …
Persistent link: https://www.econbiz.de/10011599783
Background: This study compared the methodological requirements for early health technology appraisal (HTA) by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute for Health and Care Excellence (NICE; England). Methods:...
Persistent link: https://www.econbiz.de/10011599801
The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social …
Persistent link: https://www.econbiz.de/10011599811
Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of … appraisals of medicines that were withdrawn from the German market since the introduction of AMNOG in 2011. Methods: Medications …-BA (average 'no additional benefit' rating for all AMNOG products: 47%). Of the 22 medicines, 15 (68%) were recommended by at …
Persistent link: https://www.econbiz.de/10012010779